Biological methods for diagnosing active tuberculosis or for detemining the risk of a latent tuberculosis infection progressing to active tuberculosis and materials for use therein

2:

• The method according to claim 1 further comprising the steps of:
• c) providing a control sample from an individual not afflicted with active tuberculosis (ATB);
• and
• d) measuring the expression in the control sample of GBP6 and/or BATF2;
• wherein the presence of ATB is identified in the event that the expression in the test sample of GBP6 and/or BATF2 measured in step (b) is higher than the expression in the control sample of GBP6 and/or BATF2 measured in step (d).

3:

• The method according to claim 1 further comprising the steps of:
• c) providing a control sample from an individual afflicted with active tuberculosis (ATB);
• and
• d) measuring the expression in the control sample of GBP6 and/or BATF2;
• wherein the presence of ATB is identified in the event that the expression in the test sample of GBP6 and/or BATF2 measured in step (b) corresponds to the expression in the control sample of GBP6 and/or BATF2 measured in step (d).

5:

• A method for determining the risk of a latent tuberculosis infection (LTBI) progressing to active tuberculosis (ATB) in an individual comprising the steps of:
• (a) providing a sample to be tested from the individual;
• and
• (b) measuring the expression in the test sample of GBP6 and/or BATF2;
• wherein the expression in the test sample of GBP6 and/or BATF2 is proportional to the risk of a latent TB infection progressing to an active TB infection in the individual.

8:

• The method according to claim 7, wherein the additional one or more biomarkers does not include ANKRD22;
• FCGR1A;
• SERPTNG1;
• FCGR1C;
• FCGR1B;
• LOC728744;
• IFITM3;
• EPSTI1;
• GBP5;
• IFI44L;
• GBP1;
• LOC400759;
• IFIT3;
• AIM2;
• SEPT4;
• C1QB;
• GBP1;
• RSAD2;
• RTP4;
• CARD 17;
• IFIT3;
• CASP5;
• CEACAM1;
• CARD 17;
• ISG15;
• IFI27;
• TIMM10;
• WARS;
• IFI6;
• TNFAIP6;
• PSTPIP2;
• IFI44;
• SC02;
• FBX06;
• FER1L3;
• CXCL10;
• DHRS9;
• OAS1;
• STAT1;
• HP;
• DHRS9;
• CEACAM1;
• SLC26A8;
• CACNA1E;
• OLFM4;
• or APOL6.

31:

• The method according to claim 1, wherein the method is at least 80% sensitive;
• wherein the method is at least 80% specific;
• and/or
• wherein the predicative accuracy of the method, as determined by an ROC AUC value, is at least 0.80.

41:

• A kit for determining either the presence of an ATB infection in an individual, or for determining the risk of a latent tuberculosis infection (LTBI) progressing to ATB in an individual, comprising:
• A) one or more binding agents each individually capable of binding selectively to a nucleic acid molecule encoding GBP6 and/or BATF2 or each individually capable of binding to GBP6 and/or BATF2;
• and
• B) instructions for performing the method.